Comparison · NCT00552240-4fcdf19a
Nevirapine (NVP) Plus Truvada vs Atazanavir Plus Ritonavir (ATV/r) Plus Truvada: Proportion of Patients Reporting Rash of Any Severity
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Nevirapine (NVP) Plus Truvada vs Atazanavir Plus Ritonavir (ATV/r) Plus Truvada: Proportion of Patients Reporting Rash of Any Severity. Trial comparisons, record NCT00552240-4fcdf19a. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00552240-4fcdf19a
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.28 | 0.191 | 0.39 | wilson | |
| Risk in group 2 | 0.247 | 0.164 | 0.354 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0332 | -0.106 | 0.171 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.13 | 0.666 | 1.93 | log | |
| Odds ratio, group 1 over group 2 | 1.19 | 0.576 | 2.45 | log | |
| Number needed to treat, for one more participant with the outcome on Nevirapine (NVP) Plus Truvada than on Atazanavir Plus Ritonavir (ATV/r) Plus Truvada | 30.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Nevirapine (NVP) Plus Truvada | Nevirapine 200 mg bis in die (BID) | 21 | 75 | OG000 |
| Group 2 | Atazanavir Plus Ritonavir (ATV/r) Plus Truvada | Atazanavir 300 mg plus ritonavir 100 mg quaque die (QD) | 19 | 77 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Proportion of Patients Reporting Rash of Any Severity
- Description
- Time frame
- baseline to week 52
- Population
- All treated patients
Source ClinicalTrials.gov
Trial
- Title
- Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT)
- NCT number
- NCT00552240
- Phases
- PHASE4
- Conditions
- HIV Infections
- Interventions
- tenofovir DF 300 mg QD, tenofovir DF 300 mg QD, emtricitabine 200 mg QD, emtricitabine 200 mg QD, Nevirapine 200 mg BID, Atazanavir 300 mg, Ritonavir 100 mg
- Lead sponsor
- Boehringer Ingelheim
- Results first posted
- 2011-05-23
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00552240?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00552240-4fcdf19a